Sessa Capital’s Adverum Biotechnologies ADVM Stock Holding History

Sessa Capital’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-63,871	Closed	-$2.23M	–	28
2017 Q4	$2.23M	Hold	63,871	–	–	0.27%	22
2017 Q3	$2.33M	Buy	63,871 +46,722	+272%	+$1.3M	0.26%	34
2017 Q2	$429K	Buy	+17,149	New	+$469K	0.05%	41

Other funds holding ADVM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Sessa Capital's ADVM Position: Q1 2018 in Review

Sessa Capital sold out of Adverum Biotechnologies (ADVM) in Q1 2018, closing a stake of 63,871 shares — an estimated $2.23M sold.

Sessa Capital first reported a position in ADVM in Q2 2017 and held it in 3 quarters. The position peaked at $2.33M in Q3 2017. 96 funds tracked by Wall St. Rank hold ADVM as of Q1 2018.

Sessa Capital reported no remaining Adverum Biotechnologies position as of Q1 2018 after selling out during the quarter.
Sessa Capital sold 63,871 Adverum Biotechnologies shares in Q1 2018, an estimated $2.23M.
Sessa Capital first reported a position in Adverum Biotechnologies in Q2 2017 and held it in 3 quarters.
Sessa Capital's Adverum Biotechnologies position peaked at $2.33M in Q3 2017.
96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2018.

Based on Sessa Capital's 13F filing for Q1 2018, filed 15 May 2018.